- Home
- PACS vs ICLR Comparison
PACS vs ICLR Comparison
Compare PACS & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PACS | ICLR |
|---|---|---|
| Founded | 2013 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 7.1B |
| IPO Year | 2024 | 2001 |
Fundamental Metrics
Financial Performance| Metric | PACS | ICLR |
|---|---|---|
| Price | $33.98 | $99.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $45.50 | ★ $182.08 |
| AVG Volume (30 Days) | 922.1K | ★ 3.3M |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 221.05 | N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $5,288,932,000.00 | N/A |
| Revenue This Year | $10.04 | N/A |
| Revenue Next Year | $9.30 | N/A |
| P/E Ratio | $28.25 | ★ $12.91 |
| Revenue Growth | ★ 29.32 | N/A |
| 52 Week Low | $7.50 | $66.57 |
| 52 Week High | $43.08 | $211.00 |
Technical Indicators
Market Signals| Indicator | PACS | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 39.95 | 32.80 |
| Support Level | $33.11 | $66.57 |
| Resistance Level | $35.10 | $113.88 |
| Average True Range (ATR) | 1.86 | 4.85 |
| MACD | -0.58 | 2.48 |
| Stochastic Oscillator | 9.59 | 1.79 |
Price Performance
Historical ComparisonAbout PACS PACS Group Inc.
PACS Group Inc is a post-acute healthcare company mainly focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities Its is a nursing providers in the United States based on number of facilities, with over 200 post-acute care facilities across nine states serving over 20,000 patients daily. It also provide senior care, assisted living, and independent living options in some of communities.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.